Why Cardiovascular Medicine Must Be Rebuilt Around Women's Biology
Leading researchers argue that heart disease in women is misdiagnosed and undertreated because the evidence base was built almost entirely on men.
Summary
Cardiovascular disease is the leading killer of women, yet most diagnostic standards and treatments were developed from studies dominated by men. This perspective paper in Nature Medicine argues that women have fundamentally distinct cardiovascular physiology that is rarely accounted for in clinical care. Conditions such as spontaneous coronary artery dissection, Takotsubo syndrome, and coronary vasomotor disorders affect women disproportionately but remain poorly understood and understudied. The authors call for embedding sex as a biological variable in all translational research, using emerging technologies to uncover female-specific disease mechanisms, and developing evidence-based therapies tailored to women. The paper maps a practical research roadmap to close the gap and improve heart health outcomes for women across the lifespan.
Detailed Summary
Cardiovascular disease kills more women than any other condition, yet the clinical playbook guiding diagnosis and treatment was written largely from data collected in men. This landmark Perspective in Nature Medicine, authored by researchers from the University Medical Center Utrecht and UCLA, argues that the field must be fundamentally redesigned to account for sex-specific biology — not as an afterthought, but as a core organizing principle.
Women experience cardiovascular disease differently from men at nearly every level: physiology, symptom presentation, disease trajectory, and treatment response. Yet these differences are poorly captured in clinical guidelines because the research ecosystem that generates evidence has systematically underrepresented female biology. The result is a diagnostic and therapeutic toolkit that fits women imperfectly at best.
Three conditions are highlighted as emblematic of this problem. Spontaneous coronary artery dissection (SCAD), Takotsubo syndrome, and coronary vasomotor disorders each disproportionately affect women, yet were historically under-recognized as distinct clinical entities. They remain mechanistically murky, with few evidence-based treatments. These are not rare curiosities — they represent a broader pattern of female-predominant cardiovascular disease going understudied and undertreated.
The authors propose a translational roadmap with several pillars: mandating sex as a biological variable in all cardiovascular research, leveraging emerging technologies such as multi-omics, single-cell sequencing, and AI-assisted phenotyping to decode sex-biased mechanisms, and channeling these insights into sex-specific diagnostics and therapeutics. The goal is an evidence base that reflects the biology of both sexes equally.
The clinical implications extend directly to longevity and healthspan. Heart disease is the dominant driver of premature death and disability in women, and closing the sex-evidence gap could translate into meaningful gains in both lifespan and quality of life. Caveats: the summary is based on the abstract only, and the full roadmap details and supporting data are not available without access to the complete paper.
Key Findings
- Cardiovascular disease is the leading cause of death in women, yet most clinical evidence was generated from male-dominated studies.
- Conditions like Takotsubo syndrome and SCAD disproportionately affect women but have few evidence-based treatments.
- Women's distinct cardiovascular physiology is rarely factored into clinical decision-making or research design.
- Authors propose embedding sex as a biological variable in all translational cardiovascular research.
- Emerging technologies including multi-omics and AI are identified as key tools to accelerate female-specific cardiovascular science.
Methodology
This is a Perspective article published in Nature Medicine, authored by an international team of cardiovascular researchers. It synthesizes existing evidence on sex differences in cardiovascular biology and disease, identifies research gaps, and proposes a translational roadmap. No primary data were collected; the piece is an expert-opinion and programmatic framework.
Study Limitations
The summary is based on the abstract only, as the full paper is not open access; detailed arguments and supporting data could not be reviewed. As a Perspective article, the paper presents expert opinion and a proposed roadmap rather than new empirical findings. The recommendations, while compelling, require large-scale research programs to validate and implement.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: